The Journal of Immunology, Vol 142, Issue 9 3225-3228, Copyright © 1989 by American Association of Immunologists

ARTICLES

Effects of the immunomodulator LS 2616 on lymphocyte subpopulations in murine Coxsackievirus B3 myocarditis

NG Ilback, J Fohlman, S Slorach and G Friman
Toxicology Laboratory, Swedish National Food Administration, Uppsala.

Quinoline-3-carboxamide (LS 2616) is a broadly acting immunostimulator with anti-inflammatory effects in Coxsackie virus B3-induced myocarditis in female BALB/c mice. This infection caused extensive inflammatory and necrotic lesions in the myocardium 7 days after inoculation (6.8% of tissue section area). The damaged area was reduced (to 3.7% (p less than 0.05] and the lethality decreased when LS 2616 was administered over 14 days, starting 7 days before the inoculation. The response pattern of lymphocyte subsets in situ in myocardial inflammatory lesions was elucidated by a newly developed immune histochemical staining technique. LS 2616 increased the number of class II-expressing cells 3-fold (p less than 0.01) and the CTL, Ts:Th cell ratio by 55% (p less than 0.05), whereas Lyt-1+ and TIB+ cells were unaffected. After 7 days of LS 2616 treatment, spleen lymphocyte activity tended to increase (T cells by 21% (NS) and B cells by 60% (p less than 0.05), respectively). The activity of NK cells increased by 51% (p less than 0.01). LS 2616 may thus have potential in therapy of human inflammatory disorders, such as myocarditis.

This article has been cited by other articles:

				J. H. Noseworthy, J. S. Wolinsky, F. D. Lublin, J. N. Whitaker, A. Linde, P. Gjorstrup, and H. C. Sullivan Linomide in relapsing and secondary progressive MS: Part I: Trial design and clinical results Neurology, May 9, 2000; 54(9): 1726 - 1733. [Abstract] [Full Text] [PDF]